The local injection of STZ, a glucosamine derivative of nitrosourea, at a sub-diabetogenic dose makes similar pathology to AD such as aggregation of Aβ peptides (21, 22), tau hyperphosphorylation, impairment of brain glucose transporters of neurons (23) and increased neuronal death rate (20, 24–26). This evidence concerns the gene MAPT and Alzheimer disease.